| 2101 | 35205670 | Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma. | Cancers (Basel) | 2022 Feb 12 |
1 |
| 2102 | 35213543 | Proteasome inhibition-enhanced fracture repair is associated with increased mesenchymal progenitor cells in mice. | PLoS One | 2022 |
2 |
| 2103 | 35218967 | Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF. | Acta Biomater | 2022 Apr 15 |
4 |
| 2104 | 35236820 | NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma. | Cell Death Dis | 2022 Mar 2 |
7 |
| 2105 | 35238869 | The NLRP1 Inflammasome Induces Pyroptosis in Human Corneal Epithelial Cells. | Invest Ophthalmol Vis Sci | 2022 Mar 2 |
1 |
| 2106 | 35242236 | Transient receptor potential channels in multiple myeloma. | Oncol Lett | 2022 Apr |
2 |
| 2107 | 35278160 | Metformin Relieves Bortezomib-Induced Neuropathic Pain by Regulating AMPKa2-Mediated Autophagy in the Spinal Dorsal Horn. | Neurochem Res | 2022 Jul |
17 |
| 2108 | 35291602 | Effect of Proteasome Inhibitor on Vascular Cell Adhesion Molecule-1 (VCAM-1) and Intercellular Adhesion Molecule-1 (ICAM-1) Expressions in Rat Model of Atherosclerosis. | Rep Biochem Mol Biol | 2022 Jan |
6 |
| 2109 | 35294057 | Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma. | Clin Exp Pharmacol Physiol | 2022 Jun |
2 |
| 2110 | 35307764 | Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer. | Mol Biomed | 2022 Mar 21 |
1 |
| 2111 | 35315341 | System Xc<sup>-</sup> inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance. | Cancer Lett | 2022 Jun 1 |
2 |
| 2112 | 35321428 | Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma. | Front Oncol | 2022 |
4 |
| 2113 | 35326742 | Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma. | Cancers (Basel) | 2022 Mar 21 |
4 |
| 2114 | 35344764 | Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. | EBioMedicine | 2022 Apr |
2 |
| 2115 | 35352576 | Bortezomib-Induced Ovarian Toxicity in Mice. | Toxicol Pathol | 2022 Apr |
2 |
| 2116 | 35389552 | Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma. | Clin Transl Med | 2022 Apr |
5 |
| 2117 | 35394126 | (-)-Epigallocatechin-3-gallate plays an antagonistic role in the antitumor effect of bortezomib in myeloma cells via activating Wnt/β-catenin signaling pathway. | Adv Clin Exp Med | 2022 Apr 8 |
4 |
| 2118 | 35397613 | ΔNp63α promotes Bortezomib resistance via the CYGB-ROS axis in head and neck squamous cell carcinoma. | Cell Death Dis | 2022 Apr 9 |
2 |
| 2119 | 35409095 | Specific Attenuation of Purinergic Signaling during Bortezomib-Induced Peripheral Neuropathy In Vitro. | Int J Mol Sci | 2022 Mar 29 |
1 |
| 2120 | 35434028 | Bortezomib-containing regiment in treating glomerulopathy with fibronectin deposits combined with monoclonal gammopathy of undetermined significance: a case report and literature review. | Ann Transl Med | 2022 Mar |
2 |
| 2121 | 35443750 | The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA. | Cell Death Discov | 2022 Apr 20 |
1 |
| 2122 | 35453452 | TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment. | Antioxidants (Basel) | 2022 Apr 12 |
19 |
| 2123 | 35453623 | Proteasome Inhibitors Decrease the Viability of Pulmonary Arterial Smooth Muscle Cells by Restoring Mitofusin-2 Expression under Hypoxic Conditions. | Biomedicines | 2022 Apr 9 |
3 |
| 2124 | 35462913 | SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma. | Front Pharmacol | 2022 |
5 |
| 2125 | 35467582 | Combination Therapy of an Antibody Specific for Transferrin Receptor 1 (ch128.1/IgG1) With Bortezomib or Lenalidomide Results in Increased Survival in an In Vivo Model of Human Multiple Myeloma: A Brief Communication. | J Immunother | 2022 Jun 1 |
2 |
| 2126 | 35508865 | PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling. | Ir J Med Sci | 2022 May 4 |
5 |
| 2127 | 35524959 | Bortezomib inhibits the proteasome, leading to cell death via apoptosis in feline injection site sarcoma cells in vitro. | Am J Vet Res | 2022 May 8 |
2 |
| 2128 | 35547772 | Enhanced ASGR2 by microplastic exposure leads to resistance to therapy in gastric cancer. | Theranostics | 2022 |
1 |
| 2129 | 35568791 | Heme-regulated inhibitor: an overlooked eIF2α kinase in cancer investigations. | Med Oncol | 2022 May 15 |
2 |
| 2130 | 35577689 | Multifunctional liposomal nanostructure-mediated siRNA/bortezomib co-delivery for SHARP1 knockdown in MLL-AF6 acute myeloid leukemia. | Mater Sci Eng C Mater Biol Appl | 2022 Jan 26 |
9 |
| 2131 | 35579277 | HDL-mediated reduction of cholesterol content inhibits the proliferation of prostate cancer cells induced by LDL: Role of ABCA1 and proteasome inhibition. | Biofactors | 2022 May |
1 |
| 2132 | 35589686 | The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma. | Cell Death Dis | 2022 May 19 |
8 |
| 2133 | 35596703 | Functional characterization and clinical significance of super-enhancers in lung adenocarcinoma. | Mol Carcinog | 2022 May 21 |
1 |
| 2134 | 35604822 | A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance. | Mol Cancer Res | 2022 May 23 |
10 |
| 2135 | 35637111 | TRPA1 promotes melanosome phagocytosis in keratinocytes via PAR-2/CYLD axis. | J Dermatol Sci | 2022 Jun |
4 |